Latest News and Press Releases

LIfT BioSciences expands into Ireland for manufacturing & clinical operations London, 18 November 2024– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company preparing...

Proceeds will be used to advance the Company’s IMANs into clinical trialsRaise underpins strong pre-clinical data demonstrating dual mechanism of action of LIfT’s IMANS London, 24 September 2024–...

LIfT BioSciences appoints Antonin (Tony) de Fougerolles as Chairman of its Board of Directors London, 1 July 2024– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company...

Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual Meeting London, 24 May 2024 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly...

LIfT BioSciences Awarded Innovate UK Grant to Accelerate Product Development of New IMAN Cell Therapy Variants Groundbreaking in vivo studies will be progressed to explore the impact of IMAN cell...

LIfT BioSciences appoints Dr Bo Rode Hansen and Dr Marco Gottardis to its Board of Directors London, 21 December 2023 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company...

LIfT BioSciences reports a substantial increase in cancer killing with the addition of a HER2 targeting CAR to its IMAN cell therapy Positive data supports the potential of the iN-LIfT platform to...

LIfT BioSciences heralds a new era of affordable effective cancer cell therapies simply produced from iPSCs LIfT announces successful production of first-in-class neutrophil based cell therapy from...

LIfT BioSciences heralds a new era of affordable effective cancer cell therapies simply produced from iPSCs LIfT announces successful production of first-in-class neutrophil based cell therapy from...

-         IMAN demonstrated potent direct killing of a patient derived pancreatic ductal adenocarcinoma tumouroid model  -         IMAN is the world’s first neutrophil-based cell therapy, generated...